|
|
Qing-Xiang Amy SANG, Ph.D. |
|
Research - Selected Publications - Group members - Conference Lectures & Posters - Invited Lectures & Seminars - Honors, Awards and Other information
Left to Right (front): Daniel J. Trueblood, Suzan M. Semaan, Prof. Qing-Xiang Amy Sang, Megan E. Muroski, Zahraa I. Khamis, Holly R. Monroe
Left to Right (back): Chi Ben, Mark Druen Roycik, Dr. Ziad J. Sahab, Robert G. Newcomer, Qiang Cao, Seakwoo Lee
Protein chemistry, enzymology,
biochemistry, and molecular biology of new matrix metalloproteinases (MMPs,
matrixins), tissue inhibitors of metalloproteinases (TIMPs), and membrane
proteinases/receptors, disintegrin and metalloproteinase-like proteins (ADAMs,
adamalysins), including discovering and characterizing novel human
endometase/matrilysin-2/matrix metalloproteinase-26 (MMP-26) and human
adamalysin-19/disintegrin and metalloproteinase-19/ADAM19, cDNA cloning,
expression, isolation, purification, characterization, sequencing, and chemical
modification of proteins.
Biochemical basis and cellular
and molecular mechanisms of human breast and prostate cancer cell progression, invasion,
and metastasis; role of MMPs and natural and synthetic inhibitors of MMPs in
cancer cell invasion and in angiogenesis (new blood vessel formation);
inhibition of cancer cell invasion and metastasis and inhibition of
angiogenesis by metalloproteinase inhibitors.
Biochemical and pathological
activation mechanisms of human metalloproteinases, such as the novel endometase
and adamalysin-19. Substrate specificities of MMPs and inhibition mechanisms of MMPs by
TIMPs and synthetic inhibitors. Structure-function relationships of
metalloproteinases and their inhibitors, metalloprotease/disintegrin proteins,
and extracellular matrix proteins.
Computational sequence analysis,
homology modeling, and secondary and tertiary structure prediction of MMPs,
TIMPs, and other proteins.
Bioinformatics, functional genomics, and proteomics.
Role of focal basal cell
disruption in human prostate and focal myoepithelial cell disruption in human
breast invasion. “Mutated cancer stem cell
hypothesis”. The plasticity of human cancer cells and stromal cells, epigenetic
changes of cancer cells, microenvironmental factors, tumor-stromal interactions
in cancer invasion, angiogenesis, progression, and metastasis.
Bioanalytical chemistry,
proteomics, and biomarker identification and characterization for invasive
human cancers and for cardiovascular diseases and stroke. Molecular mechanisms
of disease prevention, diagnosis, and treatment.
Molecular mechanisms of atherosclerosis,
restenosis, and blood brain barrier opening; role of metalloproteinases in
cardiovascular diseases and stroke.
Bio-nano-medicine, nanoscience and
nanotechnology in cancer, cardiovascular, stroke, obesity, and diabetes
research.
1. Q.-X. Sang,
M. Dym, and S.W. Byers (1990) Secreted metalloproteinases in testicular cells
in culture, Biol.Reprod. 43, 946-955.
2. Q.-X. Sang, W.G. Stetler-Stevenson, L.A. Liotta, and S.W. Byers (1990)
Identification of type IV collagenase in rat testicular cell culture: influence
of peritubular-Sertoli cell interactions, Biol.Reprod. 43, 956-964.
3. Q.-X. Sang (1990) Testicular metalloproteinases; regulation by hormones and
Sertoli-peritubular cell interactions in vitro, Ph.D. Dissertation, Georgetown
University, Washington D.C.
4. Q.-X. Sang, D. Grant, E.W. Thompson, W.G. Stetler-Stevenson, and S.W. Byers
(1991) Soluble laminin and arginine-glycine-aspartic acid containing peptides
differentially regulate type IV collagenase messenger RNA, activation and localization
in testicular cell culture, Biol. Reprod., 45, 387-394.
5. Q.-X. Sang, M. Dym, and S.W. Byers (1992) Proteases in seminiferous
epithelium remodeling, Matrix, supplement, 1, 404-405.
6. S. Netzel-Arnett, Q.-X. Sang, W.G.I. Moore, M. Navre, H. Birkedal-Hansen,
and H.E. Van Wart (1993) Comparative sequence specificities of human 72 and 92
kDa gelatinases (type IV collagenases) and PUMP (matrilysin), Biochemistry, 32,
6427-6432.
7. Q.-X. Sang, H. Birkedal-Hansen, and H.E. Van Wart (1995) Proteolytic and
non-proteolytic activation of human neutrophil progelatinase, Biochim. Biophy.
Acta, 1251, 99-108.
8. Q.A. Sang (1995) Specific proteolysis of ceruloplasmin by leukocyte
elastase, Biochem. Mol. Biol. Int. 37, 573-581.
9. Q.A. Sang and D.A. Douglas (1996) Computational sequence analysis of matrix
metalloproteinases, J. Protein Chem. 15, 137-160.
10. Q.A. Sang, M.K. Bodden, and L.J. Windsor (1996) Activation of human
progelatinase A by collagenase and matrilysin; activation of procollagenase by
matrilysin, J. Protein Chem. 15, 243-253.
11. M.A. Stolow, D.D. Bauzon, J. Li, T. Sedgwick, V.C.-T. Liang, Q.A. Sang, and
Y.-B. Shi (1996) Identification and characterization of a novel collagenase in
Xenopus laevis: Possible roles during frog development, Mol. Biol. Cell, 7,
1471-1483.
12. H.E. Zhau, S.-M. Chang, B.-Q. Chen, Y. Wang, H. Zhang, C. Kao, Q.A. Sang,
S.J. Pathaks, and L.W.K. Chung (1996) Androgen-repressed phenotype in human
prostate cancer, Proc. Natl. Acad. Sci. USA, 93, 15152-15157.
13. D.A. Douglas, Y.E. Shi, and Q.A. Sang (1997) Computational sequence
analysis of the tissue inhibitor of metalloproteinase family, Minireview, J.
Protein Chem. 16, 237-255.
14. C.-Y. Lin, J.-K. Wang, J. Torri, L. Dou, Q.A. Sang, and R.B. Dickson (1997)
Characterization of a novel, membrane-bound 80-kDa matrix-degrading protease
from human breast cancer cells: monoclonal antibody production, isolation, and
localization, J. Biol. Chem. 272, 9147-9152.
15. Y. E. Liu, M. Wang, J. Greene, J. Su, S. Ullrich, H. Li, S. Sheng, P.
Alexander, Q.A. Sang, and Y.E. Shi (1997) Preparation and characterization of
recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4), J. Biol. Chem.
272, 20479-20483
16. B.C. Patterson and Q.A. Sang (1997) Angiostatin converting enzyme activities
of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9), J.
Biol. Chem., 272, 28823-28825
17. H. Li, D.D. Bauzon, X. Xu, H. Tschesche, J. Cao, and Q.A. Sang (1998)
Immunological characterization of cell surface and soluble forms of
membrane-type 1 matrix metalloproteinase in human breast cancer cells and
fibroblasts, Molecular Carcinogenesis 22, 84-94
18. Y.-B. Shi and Q.A. Sang (1998) 392. Collagenase 4. In Handbook of
Proteolytic Enzymes. Editors: A.J. Barrett, N.D. Rawlings, and J.F. Woessner.
pp. 1170-1172, Academic Press,
19. Q.X. Sang (1998) Complex role of matrix metalloproteinases in angiogenesis.
Minireview. Cell Res. 8, 171-177
20. C.M. Dollery, J.R. McEwan, M. Wang, Q.A. Sang, Y.E. Liu, Y. Eric Shi (1999)
TIMP-4 is regulated by vascular injury in rats. Circulation Research 84,
498-504
21. G. Xiao, Y.E. Liu, R. Gentz, Q.A. Sang, J. Ni, I.D. Goldberg, Y.E. Shi
(1999) Suppression of breast cancer growth and metastasis by a serpin
myoepithelium-derived serine proteinase inhibitor expressed in the mammary
myoepithelial cells. Proc. Natl. Acad. Sci. USA. 96, 3700-3705
22. A.L. Stone, M. Kroeger, and Q.X. Sang (1999) Structure-function analysis of
the ADAM family of disintegrin-like and metalloproteinase containing proteins.
Review. J. Protein Chem. 18, 447-465.
23. Q.A. Sang, M.A. Schwartz, H. Li, L.W.K. Chung, and H.E. Zhau (1999)
Targeting matrix metalloproteinases in human prostate cancer.
24. C.-Y. Lin, J. Anders, M. Johnson, Q.A. Sang, and R.B. Dickson (1999)
Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease
with trypsin-like activity. J. Biol. Chem. 274, 18231-18236.
25. S.C. Mueller, G. Ghersi, S.K. Akiyama, Q.X. Sang, L. Howard, M. Pineiro-Sanchez,
H. Nakahara, Y. Yeh, and W.-T. Chen (1999) A novel protease-docking function of
integrin at invadopodia. J. Biol. Chem. 274, 24947-24952.
26. C.M. Dollery, J.R. McEwan, M. Wang, Q.A. Sang, Y.E. Liu, and Y.E. Shi
(1999) TIMP-4 is regulated by vascular injury in rats.
27. M.-C. Jia, M. A. Schwartz, and Q.A. Sang (2000) Suppression of human
microvascular endothelial cell invasion and morphogenesis with synthetic
matrixin inhibitors, Targeting angiogenesis with MMP inhibitors. Adv. Exp. Med.
Biol. 476, 181-194.
28. S. Hernandez-Barrantes, M. Toth, M.M. Bernardo, M. Yurkova, D.C. Gervasi,
Y. Raz, Q.A. Sang, R. Fridman (2000) Binding of active (57 kDa) membrane type
1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase
(TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J. Biol. Chem.
275, 12080-12089.
29. H.I. Park, J. Ni, F.E. Gerkema, L. Ding, V.E. Belozerov, and Q.-X. Sang
(2000) Identification and Characterization of Human Endometase (Matrix
Metalloproteinase-26) from Endometrial Tumor. J. Biol. Chem. 275, 20540-20544.
30. Q.-X. Sang, M.-C. Jia, M.A. Schwartz, M.C. Jaye, H.K. Kleinman, M.A.
Ghaffari, and Y.-L. Luo (2000) New thiol and sulfodiimine metalloproteinase inhibitors
and their effect on human microvascular endothelial cell growth. Biochem.
Biophys. Res. Commun. 274,780-786.
31. P. Wei, Y.G. Zhao, L. Zhuang, S. Ruben, and Q.-X. Sang (2001) Expression
and enzymatic activity of human disintegrin and metalloproteinase ADAM19
(meltrin beta). Biochem. Biophys. Res. Commun. 280, 744-755.
32. Hurst, D. R., Li, H., Xu, X., Badisa, V. L., Shi, Y. E., and Sang, Q.-X.
(2001). Development and characterization of a new polyclonal antibody
specifically against tissue inhibitor of metalloproteinases 4 (TIMP-4) in human
breast cancer. Biochem. Biophys. Res. Commun. 281,166-171.
33. S. Hernandez-Barrantes, Y. Shimura, P.D. Soloway, Q.A. Sang, and R. Fridman
(2001) Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by
MT1-MMP. Biochem. Biophys. Res. Commun. 281, 126-130.
34. Y. Jiang, M. Wang, M.Y. Celiker, Q.-X. Sang, Y.E. Liu, I.D. Goldberg, and
Y.E. Shi (2001). Stimulation of mammary tumorigenesis by systemic tissue
inhibitors of matrix metalloproteinase 4 gene delivery. Cancer Res. 61,
2365-2370.
35. Y.-G. Zhao, P. Wei, and Q.-X. Sang (2001) Inhibitory Antibodies against
Endopeptidase Activity of Human Adamalysin 19. Biochem. Biophys. Res. Commun.
289, 288-294.
36. J.
Zhang, Y.-J. Cao, Y.-G. Zhao, Q.-X.
Sang, and E.-K. Duan (2002) Expression of matrix metalloproteinase-26
and tissue inhibitor of metalloproteinase-4 in human normal cytotrophoblast
cells and a choriocarcinoma cell line, JEG-3. Mol. Human Reprod. 8, 659-666.
37. P. Wei, Y.-G. Zhao, L. Zhuang, D.R. Hurst, S. Ruben, and Q.-X. Sang (2002) Protein Engineering and Properties of Human Metalloproteinase and Thrombospondin 1. Biochem. Biophys. Res. Commun. 293, 478-488.
38. T.-B. Kang, Y.-G. Zhao, D.
39.
40. Li, Q., Wang, H., Zhao, Y., Lin, H., Sang, Q.A., Zhu, C. (2002) Identification and specific expression of matrix metalloproteinase-26 in rhesus monkey endometrium during early pregnancy. Mol. Hum. Reprod. 8, 934-940.
41. T. Kang, H. I., Park, Y. Suh, Y.-G. Zhao, H. Tschesche, and Q.-X. Sang (2002) Autolytic Processing at Glu(586)-Ser(587) within the Cysteine-rich Domain of Human Adamalysin 19/Disintegrin-metalloproteinase 19 is Necessary for its Proteolytic Activity. J. Biol. Chem. 277, 48514-48522.
42.
Y.-G. Zhao, A. Xiao, R.G. Newcomer, H.I. Park,
T. Kang, L.W.K. Chung, M.G. Swanson, H. E. Zhau, J. Kurhanewicz, and Q.-X. Sang (2003) Activation
of Pro-Gelatinase B by Endometase/Matrilysin-2 Promotes Invasion of Human
Prostate Cancer Cells. J.
Biol. Chem. 278, 15056-15064.
43. J. Zhang, Y.-J.
Cao, Y.-G. Zhao, Q.-X. Sang, and E.-K. Duan (2003) Expression and
implications of tissue inhibitor of metalloproteinases-4 in mouse embryo. Mol. Hum. Reprod. 9, 143-149.
44.
X. Liao,
J.B. Thrasher, J. Pelling, J. Holzbeierlein, Q.-X. Sang, and B. Li (2003)
Androgen stimulates matrix metalloproteinase-2 expression in human prostate
cancer. Endocrinology. 144, 1656-1663.
45.
R. Tunuguntla, D. Ripley, Q.-X. A. Sang, and
46.
47.
D. R. Hurst, M.A. Schwartz, M.A. Ghaffari, Y.
Jin, H. Tschesche, G.B. Fields, and Q.-X. Sang (2004)
Catalytic- and ecto-domains of membrane type 1-matrix metalloproteinase
have similar inhibition profiles but distinct endopeptidase activities. Biochem. J. 377, 775-779.
48.
Y.-G. Zhao, A.-Z. Xiao,
49.
T. Kang, H.
Tschesche, and Q.-X. Sang (2004) Evidence for Disulfide Involvement in
the Regulation of Intramolecular Autolytic Processing by Human Adamalysin19/ADAM19. Exp.
Cell Res. 298, 285-295.
50.
Y.-G. Man and Q.-X. Sang (2004) The Significance
of Focal Myoepithelial Cell Layer Disruptions in Human Breast Tumor Invasion: a
Paradigm Shift from the “Protease-centered” Hypothesis. Exp. Cell Res. 301,
103-118.
51.
Q.X. Sang and Y.-B. Shi (2004)
Collagenase 4. In Handbook of
Proteolytic Enzymes. Chapter 128. 2nd edition. Editors:
A.J.
52.
Q.X. Sang (2004) Matrilysin-2. In Handbook of Proteolytic Enzymes.
Chapter 135. 2nd
edition. Editors: A.J.
53.
T. Kang, R.G. Newcomer, Y.-G. Zhao, and Q.-X.
Sang (2005) Chapter 9: ADAM19: Domain structure, regulation, processing and
functions. “The
54.
W. Qiu, L. Zhao, S.-X. Bai, Q.-X. Sang, Y.-L.
Wang (2005) Expression of matrix metalloproteinase-26 in human normal placental
cytotrophoblast cells as well as its regulation by activin A. Prog. Biochem. Biophys. 32, 25-30.
55.
W. Qiu,
S.-X. Bai, M.-R. Zhao, X.-Q. Wu, Y.-G. Zhao, Q.-X. Sang, Y.-L. Wang (2005)
Spatio-temporal expression of matrix metalloproteinase-26 in human placental
trophoblasts and fetal red cells during normal placentation. Biol. Reprod. 72, 954-959 [Epub ahead of print, 2004 Dec 15].
56.
Y.-G. Man, T. Shen, Y.-G. Zhao, and Q.-X. Sang
(2005) Focal prostate basal cell layer disruptions and leukocyte infiltration
are correlated events: A potential mechanism for basal cell layer disruptions
and tumor invasion. Cancer Detect. Prev.
29, 161-169.
57.
H.-X. Wang, Y.-G. Zhao, H.M. Wang, Q. Yang,
H.-Y. Lin, Q.-X. Sang, C. Zhu (2005) Expression of adamalysin 19/ADAM19 in the
endometrium and placenta of rhesus monkey (Macaca mulatta) during early
pregnancy. Mol Hum Reprod. 11,
429-435. Epub 2005 May 18.
58.
D.R. Hurst, M.A. Schwartz,Y. Jin, M.A. Ghaffari,
P. Kozarekar, J. Cao, Q.-X. Sang (2005) Inhibition of enzyme activity and
cell-mediated substrate cleavage of membrane type 1-matrix metalloproteinase by
newly developed mercaptosulfide inhibitors. Biochem.
J. 392, 527-536. Epub 2005 Jul
19.
59.
Y.-G.
Man, T. Shen, J. Weisz, P.E. Berg, A.M. Schwartz, J.L. Mulshine, Q.-X.
Sang, and H.E. Nieburgs (2005) A subset of in situ breast
tumor cell clusters lacks expression of proliferation and progression related
markers but shows signs of stromal and vascular invasion. Cancer Detect. Prev. 29, 323-331. Epub 2005 Aug. 22.
60.
Z.J. Sahab, Y. Suh, and Q.-X. Sang (2005)
Isoelectric point-based prefractionation of proteins from crude biological
samples prior to two-dimensional gel electrophoresis. J. Proteome Res. 4,
2266-2272. Epub 2005 Nov. 18.
61.
Q.-X. Sang, Y. Jin, R.G. Newcomer, S.C. Monroe,
X. Fang, D.R. Hurst, S. Lee, Q. Cao, and M.A. Schwartz (2006) Matrix
Metalloproteinase Inhibitors as Prospective Agents for the Prevention and
Treatment of Cardiovascular and Neoplastic Diseases. Current Topics in Medicinal Chemistry. 6, 289-316. Invited review.
62.
Q. Yang, H.X. Wang, Y.G. Zhao, H.Y. Lin, H.
Zhang, H.M. Wang, Q.X. Sang, C. Zhu. (2006) Expression of tissue
inhibitor of metalloproteinase-4 (TIMP-4) in endometrium and placenta of rhesus
monkey (Macaca mulatta) during early
pregnancy. Life Sci. 78, 2804-2811. 2005 Dec 20; [Epub ahead
of print].
63.
S. Bu, C. Cao, Y. Yang, C. Miao, Z. Hu, Y. Cao,
Q. A. Sang, and
64.
D. Wildeboer, S. Naus, Q.-X. Sang,
J.W. Bartsch, and A. Pagenstecher (2006) Metalloproteinase-disintegrins ADAM8 and ADAM19 are highly regulated in
human primary brain tumors and their expression levels and activities are
associated with invasiveness. J.
Neuropathol. Exp. Neurol. 65,
516-527.
65.
S.-M. Bu, Y.-J.
Yang, C.-L. Miao, H.-J. Li, R.G. Newcomer, Q.-X. Sang, E.-K. Duan (2006)
Developmental and hormonal regulation of meltrin beta (ADAM19) expression in
mouse testes during embryonic and postnatal life. . Life Sci. 79, 2112-2118.
66.
S. Lee, K. K. Desai, K.A. Iczkowski, R.G.
Newcomer, K.J. Wu, Y.-G. Zhao, W.W. Tan, M.D. Roycik, and Q.-X. Sang (2006)
Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate
tumor. Cell Res. 16, 750-758.
67.
Z.J. Sahab,
S.M. Semaan, and Q.-X. Sang (2007) Methodology and Applications of
Disease Biomarker Identification in Human Serum. Invited Review. Biomarker
Insights. 2, 21-43.
68.
S. Lee,
69.
Z.J. Sahab, K. Iczkowski, and Q.-X. Sang (2007)
Anion Exchange Fractionation of Serum Proteins versus Albumin Elimination. Anal. Biochem. 368, 24-32.
70.
J. Hu, P.E. Van den Steen, Q.-X. Sang , and G.
Opdenakker (2007) Matrix metalloproteinase inhibitors as therapy for
inflammatory and vascular diseases. Nature
Reviews Drug Discovery. 6,
480-498. Invited review.
71.
M.E. Muroski, M.D. Roycik, R.G. Newcomer, P.E.
Van den Steen, G. Opdenakker, H.R. Monroe, Z.J. Sahab, and Q.-X. Sang (2008)
Matrix Metalloproteinase-9/Gelatinase B is a Putative Therapeutic Target of
Chronic Obstructive Pulmonary Disease and Multiple Sclerosis. Current Pharmaceutical Biotechnology 9, 34-46. Invited Review.
72.
Y. Zhao, C.E. Lyons Jr.; A. Xiao, D.J.
Templeton, Q.A. Sang, K. Brew, I.M. Hussaini (2008) Urokinase directly
activates matrix metalloproteinase-9: A potential role in glioblastoma
invasion. Biochem. Biophys. Res. Commun. 369, 1215-1220.
Back to the top
Graduate, Undergraduate
Students, Postdoctoral and other Research Assistants/Associates Trained in Dr.
Sang's Lab
Graduate Students:
Former: Delbert D.
Bauzon, Paul H. Schmid, Brian C. Patterson, Anne L. Stone, Shawn A. Clark, Vladimir
E. Belozerov, Andrew A. Korostelev, Laura A. Mertz, Cheri Bunder, Bradley D.
Prater, Sonia Hernandez-Barrantes, Fuli Yu, Georgia A. Wilkie, Jocelyn Dudley, Elena Filenova,
Faqing Yuan, Mitesh Jivan,
Douglas R. Hurst (graduated with a Ph.D. degree in
Biochemistry in Dec. 2003).
Current position: NIH postdoctoral fellow, University of
Alabama at Birmingham, Birmingham, Alabama.
Ziad Sahab (graduated with a Ph.D. degree in
Bioanalytical Chemistry in Dec. 2005)
Current
position: Postdoctoral Research
Associate, Georgetown University Lombardi Cancer Center in Washington D.C.
Yewseok Suh (graduated with a Ph.D. degree in
Biochemistry in Aug. 2006)
Current
position: Postdoctoral Research
Associate, University of Wisconsin, Madison, Wisconsin.
Daniel Trueblood (graduated with a M.S. degree in
Biochemistry in May 2007)
Current
Position: Officer in the US Air Force
Seakwoo Lee (graduated with a Ph.D. degree in
Biochemistry in Aug. 2007)
Current
position: Postdoctoral Research
Associate, Johns Hopkins University, Baltimore, Maryland.
Robert G. Newcomer (graduated with a Ph.D. degree in
Biochemistry in Aug. 2007)
Current
position: Scientist and Scientific
Writer. Upside Endeavors, LLC, Sanatoga, Pennsylvania.
Current: Qiang Cao, Mark Dru Roycik, Suzan Marie
Semaan, Chi Ben, Zahraa I. Khamis, and Megan E. Muroski.
Undergraduate Students:
Former: Annette
Vaughan, Damon A. Douglas, Rachel K. Stilwell, Scott A. Gass, Michael B.
Dillhyon, Ian Davis, Mayra Martin, James Mike Magill, Edwin Alex Melendez,
Nneka Lotea Ifejika, William Richard Mansfield, III, Karyn M. Usher, Charles
Quincy Adams, Stacie Kemp Wilensky, Andy Rodriguez, Ferry E.
Gerkema, Marjoleine H. Bleijenberg,
Sara C. Monroe, Cyrus A. Monroe, Joseph Lichter, Katie Berry, Shelbourn (Shelby) Kent, Ehsan (Sonny) Achtchi, Margie Coryn, Melanie
Overland, Colesha Jackson, Kevin K. Desai, Jennifer
Walker, Amjad Asker, Megan E. Muroski,
and Holly Monroe.
Current: Kelli
Wisniewski, Yangguang Ou.
Postdoctoral and other Research Assistants
/Associates:
Former: Hui Li,
ShiDeng Bao, Dr. XinYun Xu, Dr. Wan-Qian Zhao, Dr. Meng-Chun Jia, Veera Lakshmi
Devi Badisa, Dr. Michaela Kroeger, J. Mike Magill, Dr. Laurence D. Covassin,
Mr. Asad Ullah, Dr. Hyun I.
Park, Dr. Tiebang Kang, Dr. Aizhen Xiao, and Dr. Yunge Zhao
Back to the top
Lectures and posters
presented in conferences
1. Q.-X. Sang, M. Dym, and S.W. Byers (1988) Sertoli cell plasma
membrane associated and secreted plasminogen-independent proteases (PIPs),
J.Cell Biol. 107, 616a
2. Q.-X.Sang, M. Dym, and S.W. Byers (1988) Characterization of Sertoli cell
plasma membrane associated and secreted plasminogen-independent proteases, in
Regulation of Testicular Function: Signaling Molecules and Cell-Cell
Communications, 10th Annual Testis Workshop, 71a
3. S.W. Byers, Q.-X. Sang, H.N. Dai, J. Beaudry, and B. Hoxter (1989) The
Sertoli cell plasma membrane and plasminogen-independent proteases in
seminiferous epithelium remodeling, in Serono Symposia Review, Supplement I, IV
International Congress of Andrology, 21a
4. S.W. Byers, Q.-X. Sang, H.N. Dai, J. Beaudry, and B. Hoxter (1989) Isolation
and characterization of Sertoli cell plasma membrane and junctional
specializations, Anatomical Record 223, 20a
5. Q.-X. Sang, and S.W. Byers (1989) Matrix metalloproteinases in rat
testicular cell culture, J.Cell Biol. 109, 135a
6. Q.-X. Sang, D. Grant, E.W. Thompson, W.G. Stetler-Stevenson, and S.W. Byers
(1990) Soluble laminin and RGD-containing peptides differentially regulate type
IV collagenase mRNA, activation and localization in testicular cell culture,
J.Cell Biol. 111, 15a
7. Q.-X. Sang, H. Birkedal-Hansen, and H.E. Van Wart, (1993) Activation of
human neutrophil progelatinase/type IV collagenase by matrilysin and fibroblast
collagenase, Molecular Biology of the Cell (suppl.), 4, 287a
8. Q.-X. Sang, H. Birkedal-Hansen, and H.E. Van Wart (1994) Activation of human
progelatinase A and B (type IV collagenases) by matrilysin and fibroblast
collagenase, Molecular Genetics of Tumor Progression and Metastasis -- A
Special Conference of the American Association for Cancer Research, page B-26
9. Q.-X. Sang, H. Birkedal-Hansen, and H.E. Van Wart (1995) Regulation of human
type IV collagenase activity. The American Cancer Society, Florida Division,
Inc., 18th Annual Seminar of
10. Q.-X. Sang and J.M. Caffrey (1995) Hydrolysis of porcine ceruloplasmin by
human leukocyte elastase. Cambridge Healthtech Institute's Angiogenesis
Antagonists -- New Cancer Strategies.
11. Q.-X. Sang, H. Birkedal-Hansen, and H.E. Van Wart (1995) Proteolytic
activation of progelatinases A and B. Gordon Research Conference on Matrix
Metalloproteinase,
12. Q.A. Sang and H. Li (1996) Regulation of breast cancer type IV collagenase
activity by laminin and laminin-derived peptides. Proteases and Protease
Inhibitors in Cancer. A Special Conference of American Association for Cancer Research,
page A-31.
13. D.A. Douglas and Q.A. Sang (1996) Computational sequence analysis of the
matrix metalloproteinase family. The American Cancer Society, Florida Division,
Inc., 19th Annual Seminar of
14. D.D. Bauzon, M.A. Stolow, Y.-B. Shi, and Q.A. Sang (1996) Identification
and characterization of a novel collagenase in Xenopus laevis. The American
Cancer Society, Florida Division, Inc., 19th Annual Seminar of
15. Hui Li and Q.A. Sang (1996) Regulation of breast cancer type IV collagenase
activity by laminin and laminin-derived peptides. The American Cancer Society,
Florida Division, Inc., 19th Annual Seminar of
16. Q.A. Sang, H. Li, and D.D. Bauzon (1996) Activation of breast cancer type
IV collagenases. Gordon Research Conference on Basement Membrane.
17. Q.A. Sang and D.A. Douglas (1996) Computational sequence analysis of matrix
metalloproteinases and tissue inhibitors of metalloproteinases, Gordon Research
Conference on Proteolytic Enzymes and Their Inhibitors.
18. D.D. Bauzon, J. Li, M.A. Stolow, Y.-B. Shi, and Q.A. Sang (1996)
Biochemical characterization of a novel collagenase from Xenopus laevis. Mol.
Biol. Cell 7, 59a.
19. H. Li, D.D. Bauzon, and Q.A. Sang (1997) Cell surface metalloproteinase in
breast cancer cells and fibroblasts. Fibronectins, Integrins and Related
Molecules, Gordon Research Conference.
20. H. Li, D.D. Bauzon, and Q.A. Sang (1997) Breast cancer membrane type-1
matrix metalloproteinases. Poster #34, American Chemical Society,
21. B. C. Patterson and Q.A. Sang (1997) Potential angiostatin converting
enzyme activities of human matrilysin and gelatinase B. American Chemical
Society, Florida Sections.
22. D. E. Bauzon, J.M. Magill, L.J. Windsor, J.W. Li, Y.-B. Shi, and Q.A. Sang
(1997) Hydrolysis of type I, II, and III collagens by frog collagenase-4.
American Chemical Society,
23. Q.X.A. Sang, Y.E. Shi, and D.A. Douglas (1997) Computational sequence
analysis of matrix metalloproteinases and their tissue inhibitors. Cambridge
Healthtech Institute's Beyond the Human Genome Project, from Genes to Proteins
and Bioinformatics.
24. D.D. Bauzon, L.J. Windsor, J. Li, Y.-B. Shi, and Q.A. Sang, Substrate
specificities of frog collagenase-4 (MMP-18). Gordon Research Conference on
Matrix Metalloproteinase,
25. H.Li, D.D. Bauzon, and Q.A. Sang, Novel human breast cancer cell surface
metalloproteinases. Gordon Research Conference on Cancer, Salve
26. B.C. Patterson and Q.A. Sang, Human matrilysin and gelatinase B, candidates
for angiostatin converting enzymes. Gordon Research Conference on Angiogenesis
and Microcirculation, Salve
27. S.C. Mueller, G. Ghersi, S.K. Akiyama, Q.X.A. Sang, L. Howard, M.
Pineiro-Sanchez, H. Nakahara, Y. Yeh, and W.-T. Chen (1997) Collagen induces 1
integrin docking of a membrane-bound gelatinase, seprase, at plasma membrane
sites of tumor cell invasion. Mol. Biol. Cell (suppl.), 8, 75a.
28. Q.X.A. Sang, Y.E. Shi, and H. Li (1998) Biochemical characterization of
human tissue inhibitor of metalloproteinase-4. Keystone Symposium on
Angiogenesis and Vascular Remodeling.
29. Q.X.A. Sang, H. Li, X. Xu, Y.E. Shi, M.-C. Jia. Tissue inhibitor of
metalloproteinase-4 in human breast cancer and endothelial cells. Proeases and
Protease Inhibitors in Cancer. A Special Conference of American Association for
Cancer Research and ACTA Pathologica Microbiologica Immunologica
30. Q.X.A. Sang. Complex role of matrilysin and type IV collagenases in
angiogenesis. Oral Presentation. In Vascular Endothelium: Mechanisms of Cell
Signaling. Edited by J.D. Catravas, A.D. Callow,
31. Q.X.A. Sang, X. Xu, Y.E. Shi, H. Li. Tissue inhibitor of
metalloproteinase-4 in human breast cancer and endothelial cells. In Vascular
Endothelium: Mechanisms of Cell Signaling. Edited by J.D. Catravas, A.D.
Callow,
32. Q.X.A. Sang, M.A. Schwartz, H. Li, L.W.K. Chung, and H.E. Zhau. Targeting
matrix metalloproteinases in human prostate cancer. Inhibition of Matrix
Metalloproteinases: Therapeutic Applications. A
33. Q.X.A. Sang, M.A. Schwartz, H. Li, L.W.K. Chung, and H.E. Zhau. Inhibition
of prostate cancer matrix metalloproteinases. Metalloproteases: Chemistry,
Biology and Medicine. A Keystone Symposium on Molecular & Cellular Biology,
34. M.-C. Jia, M.A. Schwartz, V.L.D. Badisa, M.A. Ghaffari, Y.-L. Luo, M.C.
Jaye, H.K. Kleinman, Q.A. Sang. Matrixins and metalloproteinase inhibitiors in
human endothelial cell growth, differentiation, and angiogenesis. 5th Biannual
International Conference on Angiogenesis: From the Molecular to Integrative
Pharmacology.
35. M.-C. Jia, M.A. Schwartz, V.L.D. Badisa, M.A. Ghaffari, Y.-L. Luo, M.C.
Jaye, H.K. Kleinman, Q.A. Sang. Inhibition of human endothelial cell growth,
differentiation, and angiogenesis by novel synthetic metalloproteinase
inhibitors. Gordon Research conference on Matrix Metalloproteinases.
36. Q.X.A. Sang, M.A. Schwartz, and M.-C. Jia. Targeting angiogenesis and
cancer invasion with metalloproteinase inhibitors. 2nd International Conference
on Protease Inhibitors.
37. H.I. Park, J. Ni, F.E. Gerkema, L. Ding, V.E. Belozerov, and Q.-X. Sang.
Expression, activation, and inhibition of a novel matrix metalloproteinase,
endometase. An International Symposium "Proteinase Inhibitors and
Activators" Strategic Targets for Therapeutic Intervention.
38. H.I. Park, J. Ni, F.E. Gerkema, L. Ding, V.E. Belozerov, and Q.-X. Sang.
Endometase, a Novel Matrixin Derived from Human Endometrial Tumor and
Endothelium. NATO Conference on Vascular Endothelium: Source and Target of
Inflammatory Mediators. NATO Advanced Study Institute.
40. H.I. Park, J. Ni, F.E. Gerkema, L. Ding, V.E. Belozerov, and Q.-X. Sang.
Biochemical characterization of human endometase (MMP-26) from endometrial
tumor. ECM 2000: International Conference on the Biology and Pathology of the
Extracellular Matrix.
41.
42. Q.-X.A. Sang, H.I. Park, J. Ni, D. Liu, F.E. Gerkema, and Y.-G. Zhao. Discovery
of a novel matrix metalloproteinase (MMP-26), endometase, from human
endometrial and prostate cancers. 5th Joint Conference of the American
Association for Cancer Research and the Japanese Cancer Association,"
Molecular Biology and New Therapeutic Strategies: Cancer Research in the 21st
Century". Poster B1.
43. Q.-X.A. Sang, J. Ni, F.E. Gerkema, D. Liu, V.E. Belozerov, and
44. Y.-G.Zhao, P. Wei, L. Zhuang, S. Ruben, and Q.-X.A. Sang (2001). Human
disintegrin and metalloproteinase ADAM19 (hADAM19): Cloning, expression and
enzymatic characterization. American Society for Biochemistry and Molecular
Biology Annual Meeting held jointly with Experimental Biology.
45. D.R.Hurst, M.A. Schwartz, M.A. Ghaffari, H. Tschesche, and Q.-X.A. Sang
(2001). New thiol metalloproteinase inhibitors: an examination of the catalytic
domain of membrane-type 1 matrix metalloproteinase in human breast cancer.
American Society for Biochemistry and Molecular Biology Annual Meeting held
jointly with Experimental Biology.
46. Y.-G. Zhao, P.Wei, L. Zhuang, D.R. Hurst, S. Ruben and Q.-X. Sang.
Immunological and enzymatic characterization of human disintegrin and
metalloproteinase 19 (hADAM 19)/Meltrin beta.
47.
48. Y.-G. Zhao, P. Wei, L. Zhuang, L.D. Covassin, D.R. Hurst, S. Ruben, and
Q.-X. Sang. Human disintegrin and metalloproteinase 19, expression,
characterization, and potential functions. International Congress on
Membrane-bound Proteolytic Enzymes and Cancer".
49.
50. Y.-G. Zhao, P. Wei, L. Zhuang, L.D. Covassin, D.R. Hurst, S. Ruben, and
Q.-X. Sang. Identification of human adamalysin-19 (disintegrin and
metalloproteinase 19) and its putative functions in cardiovascular system and
cancer. 6th Biannual International Conference on Angiogenesis: Basic Science
and Clinical Developments.
51.
52.
53. D.R. Hurst, M.A. Schwartz, Y.-H. Jin, M.A. Ghaffari, H. Tschesche, and
Q.-X. Sang. New mercaptoalkylsulfide inhibitors targeting membrane-type 1
matrix metalloproteinase. 2nd General Meeting of the International Proteolysis
Society associated with the International Conference on Protease Inhibitors.
Freising,
54.
55. Y.-G. Zhao, P. Wei, L. Zhuang, D.R. Hurst, L.D. Covassin, S. Ruben, and
Q.-X. Sang. Human membrane adamalysin-19 expression, enzymatic activity, and
neutralizing antibodies. 2nd General Meeting of the International Proteolysis
Society associated with the International Conference on Protease Inhibitors.
Freising,
56.
57.
58. T. Kang, Y.-G. Zhao, D.
59. Y.-G. Zhao, H.I. Park, M.A. Schwartz,
M.-C. Jia, and Q.-X. Sang. A New
Metalloproteinase in Cancer Progression and Angiogenesis. Pathobiology
of Cancer Workshop. American
Association for Cancer Research. Keystone,
60. D.R. Hurst, M.A. Schwartz, Y.-H. Jin, M.A.
Ghaffari, H. Tschesche, and Q.-X. A. Sang.
Targeting membrane type 1-matrix metalloproteinase with
mercaptoalkylsulfide inhibitors. Era of Hope, Department of Defense Breast
Cancer Research Program Meeting.
Proceedings vol. II, p27-4.
61. Y.-G.
Zhao, A.-Z. Xiao, T. Kang, L.W.K. Chung, M.G. Swanson, H.E. Zhau, J.
Kurhanewicz, and Q.-X.A. Sang. Putative
Role of Endometase/Matrilysin-2 in Prostate Cancer Cell Invasion. An American
Association for Cancer Research Special Conference on Proteases, Extracellular Matrix, and Cancer.
62.
63. D.R. Hurst, M.A.
Schwartz, Y. Jin, H. Tschesche, and Q.-X.A. Sang. Exploring the Active Site of Membrane Type
1-Matrix Metalloproteinase with New Mercaptosulfide Inhibitors. 54th
Southeast Regional Meeting of the American Chemical Society.
64. T. Kang, H.
Tschesche, and Q.-X. A. Sang. Regulation
of Enzyme Stability by the Cysteine Residues of the Residual Cysteine-rich
Domain of the C-terminal Fragment Retained by the Autocatalytic Processing at
Glu586-Ser587
of Human Adamalysin 19/ADAM19. Gordon
Research Conference on Matrix Metalloproteinase. Conference Chairpersons: Christopher M. Overall and Zena Werb. Big Sky,
65. Y.-G.
Zhao, A.-Z. Xiao,
66. Y.-G.
Man, R. Mattu, R. Zhang, M. Yousefi, Q.X.A. Sang, and T. Shen (2003) A subset
of normal and hyperplastic appearing mammary ductal cells display invasive
features. 26th Annual San Antonio Breast Cancer Symposium.
67. Y.-G.
Man, R. Zhang, R. Mattu, T. Shen, and Q.X.A. Sang (2003) A subset of mammary
epithelial cells overlying focally disrupted myoepithelial cell layers shows an
unusual immunostaining pattern for proliferation-related proteins. 26th
Annual San Antonio Breast Cancer Symposium.
68. Q.-X.
Sang, H.I. Park, Y. Jin, Y. Zhao, A. Xiao, D.R. Hurst, C.A. Monroe, S. Lee,
R.G. Newcomer, M.A. Schwartz (2004) Inhibition of endometase/matrilysin-2 by
tissue inhibitors of metalloproteinases and new synthetic mercaptosulfide
inhibitiors and implications in human prostate and breast cancers. Proc.
Am. Assoc. Cancer Res. 45, Abst.
No. 1835,
69. Y.-G.
Man, T. Shen, Y. Zhao, and Q.-X. Sang (2004) Focal prostate basal cell layer
disruptions and leukocyte infiltration are correlated events: implications for
tumor invasion. Proc. Am. Assoc. Cancer
Res. 45, Abst. No. 1775,
70. Y.-G.
Man, T. Shen, Y. Zhao, and Q.-X. Sang (2004) Morphologically comparable
prostate acini and ducts with and without a focal basal cell layer disruption
have a different cell proliferation rate: implications for tumor invasion. FASEB J. 18, p. A1183. Abst. No. 786.11.
71.
72. Y.-G.
Man, T. Shen, Y.-G. Zhao, and Q.-X. A. Sang (2004) Prostate basal cell layer
disruptions and leukocyte infiltration (Endometase/matrilysin-2 in invasion and
inflammation). 10th Prouts Neck Meeting on Prostate Cancer. Late
Stage Prostate Cancer: a Multidisciplinary Approach. pp. 60.
73. S.
Lee and Q.-X. Sang (2004) The role of calcium ions in the structure and
function of matrixmetalloproteinase-26. 56th Southeast Regional Meeting of the
American Chemical Society.
74. Y.-G.
Man and Q.-X. A. Sang (2004) Human prostate basal cell layer disruptions and
leukocyte infiltration. American Association for Cancer Research Special
Conference on Basic, Translational, and Clinical Advances in Prostate Cancer.
Poster A5.
75. Y.
Zhao, A. Xiao, Y. Jin, M.A. Schwartz, and Q.-X. Sang (2004) Inhibition of
MDA-MB-435 cell invasion by a synthetic matrix metalloproteinase inhibitor. The
American Society for Cell Biology 44th Annual Meeting,
76. Q.-X.
Sang, Y.-G. Zhao, and Y.-G. Man (2005) Mechanism of human prostate cancer
invasion: Basement membrane degradation and basal cell layer disruption. Proceedings of American Association for
Cancer Research 46, page 1106, Poster #4689.
77. Y.-G.
Man, P.E. Berg, Q.-X. Sang (2005) Differential expression of tumor invasion
related proteins in cells overlying focally disrupted myoepithelial cell layers
and adjacent cells within the same duct. Era of Hope: Proceedings of Department of Defense Breast Cancer Research Program
Meeting Poster P10-5, p75.
78. Y.
Zhao, A. Xiao, and Q.-X. Sang (2005) The novel three dimensional cell culture
system for human breast cancer: cancer invasion and cell-cell interaction. Era
of Hope: Proceedings of Department of
Defense Breast Cancer Research Program Meeting Poster P59-24, p417.
79. M.E.
Muroski, D. R. Hurst, Y. Jin, M.A. Schwartz, and Q.-X. Sang (2005) Potency and
Selectivity of Selected Metalloproteinase Inhibitors. 37th Annual
Southeast Regional American Chemical Society Undergraduate Research Conference
hosted by
80. M.E.
Muroski, D.R. Hurst, Y. Jin, M.A. Schwartz, and Q.-X. Sang (2005) Potency and
Selectivity of Selected Metalloproteinase Inhibitors. 37th Annual Southeast
Regional American Chemical Society Undergraduate Research Conference hosted by
81. K.K.
Desai, R.G. Newcomer, K.A. Iczkowski, Y.-G. Zhao, M.D. Roycik, and Q.X.A. Sang
(2005) Expression levels of tissue inhibitor of metalloproteinases-4 and matrix
metalloproteinase-26 correlate with the invasive potential of HGPIN in human
prostate tissue. 37th Annual Southeast Regional American Chemical Society
Undergraduate Research Conference,
82. Y.G.
Man and Q.-X. Sang (2005) Myoepithelial cell layer disruption and human breast
cancer invasion. Breast Cancer Research.
Vol. 7, Suppl. 2, June 2005. Poster
P3.06, p. S33. The Third International Symposium on the Molecular Biology of
Breast Cancer.
83. Sahab,
Z.J., and Sang, Q.-X. (2005) Albumin elimination from human
plasma. Abstracts of Papers, 230th American Chemical Society National
Meeting,
84. Sahab, Z.J., Suh, Y., and Sang, Q.-X. (2005) Pre-fractionation of proteins from crude biological samples prior to 2-D gel electrophoresis. Abstracts of Papers, 230th American Chemical Society National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 , ANYL-151. CODEN: 69HFCL AN 2005:736143.
85. Sahab,
Z.J., Suh, Y., and Sang, Q.-X. (2005) Narrow isoelectric-point based
pre-fractionation of proteins from crude biological
samples. Abstracts of Papers, 230th American Chemical Society
National Meeting,
86. D.R.
Hurst, M.A. Schwartz,Y. Jin, M.A. Ghaffari, P. Kozarekar, J. Cao, Q.-X. Sang
(2005) Inhibition of enzyme activity and cell-mediated substrate cleavage of
membrane type 1-matrix metalloproteinase by newly developed mercaptosulfide
inhibitors. Matrix Metalloproteinases
Gordon Research Conference, Big Sky,
87. Y. Jin, Q. Cao, Q.-X. Sang and M.A. Schwartz (2006) Zinc Metalloproteinase Inhibitors with 1,2-Dihydroxy benzene and 3-Hydroxy-4-pyrone as Zinc Binding Groups. 231st American Chemical Society National Meeting & Exposition, March 26-30, 2006, Atlanta, Georgia.
88. S. Lee and Q.-X. Sang (2006) Effects of human endometase/matrilysin-2/MMP-26 on the invasive potential and protein expression patterns of a human breast cancer cell line MDA-MB-231. American Chemical Society (ACS) Paper #36620 - 58th Southeast Regional Meeting. November 1-4, 2006. Augusta, Georgia.
89. Q.-X. Sang, S. Lee, H.I. Park, Y.-G. Zhao, Y. Jin, and M.A. Schwartz (2007) Unique Structure and Function of Endometase/Matrilysin-2, a Putative Cancer Biomarker. Invited Plenary Talk. American Chemical Society, Florida Section Meeting, Orlando, Florida. May 11, 2007. Talk number 115.
90. R.G. Newcomer, M.D. Moussallem, T.C. S. Keller, J.B. Schlenoff, and Q.-X. Sang. Divergent Human Vascular Smooth Muscle Cell Response to Polyelectrolyte Multilayer Bio-Interfaces. Invited Talk. American Chemical Society, Florida Section Meeting, Orlando, Florida. May 11, 2007. Talk number 114.
91. S.M. Semaan, Z.J. Sahab, Y. Suh, and Q.-X. Sang. Extraction of Basic Proteins using Batch Anion Exchange Chromatography Prior to Profiling and Identification. American Chemical Society, Florida Section Meeting, Orlando, Florida. May 10-12, 2007. Poster number 224.
92. Y. Jin, Q. Cao, C. Ben, Q.-X. Sang, and M.A. Schwartz. Design and Syntheses of Novel MMP Inhibitors Containing a Mercaptosulphonamide Zinc-bind Group. Invited Talk. American Chemical Society, Florida Section Meeting, Orlando, Florida. May 10, 2007. Talk number 46.
93. Q.-X. Sang, S. Lee, H.I. Park, Y.G. Zhao, Y. Jin, K.K. Desai, and M.A. Schwartz (2007) Endometase/Matrilysin-2/MMP-26 is a Putative Biomarker for Early Stage of Cancer of Human Breast and Prostate. Gordon Research Conference on Matrix Metalloproteinases. II Ciocco, in Lucca (Barga), Italy. June 3-8, 2007.
94. Q.-X. Sang, Y. Jin, Y.-G. Zhao, H.I. Park, A.-Z. Xiao, R.G. Newcomer, T. Kang, S. Lee, L.W.K. Chung, H.E. Zhau, and M.A. Schwartz (2007) Endometase/Matrilysin-2/Matrix Metalloproteinase-26 as a Putative Biomarker for Early Stage of Human Prostate Cancer. Innovative Minds in Prostate Cancer Today (IMPaCT) Meeting, Congressionally Directed Medical Research Programs, Prostate Cancer Research Program. Atlanta, Georgia. September 5-8, 2007.
95. Y. Yang, J.F. Thompson, E.J. Walker, E. Candelario-Jalil, E.Y. Estrada, L. Li, R.R. Reichard, R. Khokha, C. Ben, Q.-X. A. Sang, L.A. Cunningham, G.A. Rosenberg (2007) Tissue inhibitor of metalloproteinase-3 (TIMP-3) facilitates delayed oligodendrocyte death in focal cerebral ischemia in rodent. Neuroscience 2007. San Diego, California. November 3-7, 2007.
96. Q.-X. Sang, Z.J. Sahab, Y.-G. Man, R.G. Newcomer (2008) Differential protein expression between microdissected estrogen-receptor positive and negative human breast cancer tissues. Invited Talk. American Chemical Society, Florida Section FAME Meeting, Orlando, Florida. May 9, 2008. Talk number 58.
97. Q.-X. Sang (2008) Protein Biomarkers of Human Breast and Prostate Cancer Invasion and Progression at the Interface of Benign and Malignant Tumors. BIT’s Annual World Cancer Congress 2008. Invited talk at the session 32 on Cancer Invasion and Metastasis. Shanghai, China. June 13, 2008
.
Back to the top
Invited lectures /
Seminars
1. Testicular metalloproteinases; Regulation by hormones and
Sertoli-peritubular cell interactions. Mid-Atlantic Reproductive Biology
Conference,
2. Testicular metalloproteinases; Regulation by hormones,
mesenchymal-epithelial cell interactions, and ECM components. The
3. Identification and regulation of type IV collagenase in testicular cell
culture. The
4. Activation of human neutrophil gelatinase (type IV collagenase)--is there an
internal human matrix metalloproteinase activation cascade? The
5. Activation mechanisms of human matrix metalloproteinases; regulation of the
activity of human neutrophil gelatinase/type IV collagenase. Universidad
Autonoma Metropolitana de Iztapalape,
6. Activation of human matrix metalloproteinase-9 (Gelatinase B). National
Institutes of Health.
7. Matrix metalloproteinases in cancer cell invasion and metastasis.
8. Activation mechanisms of matrix metalloproteinases.
9. Regulation of human type IV collagenase activity. The American Cancer
Society, Florida Division, Inc., 18th Annual Seminar of
10. Human breast cancer cell-fibroblasts interaction induced membrane-type
matrix metalloproteinase-1 (MT1-MMP) production and gelatinase activation.
11. Activation of human neutrophil gelatinase B and fibroblast gelatinase A by
matrilysin and human fibroblast collagenase; Human breast cancer
cell-fibroblasts interaction induced membrane-type matrix metalloproteinase-1
(MT1-MMP) production and gelatinase activation.
12. Regulation of Matrix Metalloproteinases, from Corneal Ulcer to
Angiogenesis.
13. Regulation of Matrix Metalloproteinases.
14. Novel Matrix Metalloproteinases, Implications in Metamorphosis and
Metastasis.
15. Biochemical Characterization of Collagenases, Potential Roles in
Development and Cancer.
16. Activation, Inhibition, and Substrate Specificities of Gelatinases and
Collagenases. Northwestern University,
17. The Collagenase Family in Metamorphosis and Metastasis.
18. Biochemical studies of the matrix metalloproteinases (Matrixins). Symposium
on Biomolecular Structure and Function. American Chemical Society,
19. Antibody Production and Characterization of a Breast Cancer Surface
Metalloproteinase.
20 . The Matrixin Family of Metalloenzymes and Their Inhibitors.
21. Matrix metalloproteinases and their inhibitors. American Chemical Society,
22. Complex role of matrilysin and type IV collagenases in angiogenesis. Oral
Presentation. In Vascular Endothelium: Mechanisms of Cell Signaling. Edited by
J.D. Catravas, A.D. Callow,
23. Matrixins and Metalloproteinase Inhibitors in Cancer and Cardiovascular
Disease.
24. Biochemical Investigations of Metalloproteinases in Angiogenesis and
Reproduction. National Research Institute for Family Planning and World Health
Organization Collaborating Center for Research in Human Reproduction,
25. Biochemical Characterization of Matrixins and Metalloproteinase Inhibitors
in Cancer and Angiogenesis. State Key Laboratory of Reproductive Biology,
26. Activation, Inhibition, and Substrate Specificities of Metalloproteinases
and Their Role in Cancer and Angiogenesis.
27. Matrixins and Metalloproteinase Inhibitiors in Human Endothelial Cell
Growth, Differentiation, and Angiogenesis. 5th Biannual International
Conference on Angiogenesis: From the Molecular to Integrative Pharmacology.
28. Targeting Collagen-degrading Matrixins in Angiogenesis and Cancer. Human
Genome Sciences, Inc.
29. Extracellular Matrix Degrading Metalloproteinases in Development and
Angiogenesis.
30.Targeting angiogenesis and cancer invasion with metalloproteinase
inhibitors. 2nd International Conference on Protease Inhibitors.
31. Expression, activation, and inhibition of a novel matrix metalloproteinase,
endometase. An International Symposium "Proteinase Inhibitors and
Activators" Strategic Targets for Therapeutic Intervention.
32. Identification and Characterization of Human Endometase (Matrix
Metalloproteinase-26) from Endometrial Tumor. Max-Planck-Institute for
Biochemistry,
33. Endometase, a Novel Matrixin Derived from Human Endometrial Tumor and
Endothelium. International Conference on Vascular Endothelium: Source and
Target of Inflammatory Mediators. NATO Advanced Study Institute.
34. Cloning, Expression, and Enzymatic Characterization of Human Endometase
(Matrix Metalloproteinase-26) from Endometrial Tumor.
35. Discovery, Expression, and Biochemical Characterization of Human Endometase
(Matrix Metalloproteinase-26) from Endometrial Tumor.
36. Discovery and Biochemical Studies of Human Cancer Endometase (Matrix
Metalloproteinase-26).
37. Endometase, a Novel Matrix Metalloproteinase (MMP-26) Derived from Human
Cancers. Provid Research (Division of Praecis Pharmaceuticals Inc),
38. Discovery and Biochemical Studies of a Novel Metalloproteinase in Cancer.
39. Human disintegrin and metalloproteinase 19, expression, characterization,
and potential functions. International Congress on Membrane-bound Proteolytic
Enzymes and Cancer.
40. Identification of human adamalysin-19 (disintegrin and metalloproteinase
19) and its putative functions in cardiovascular system and cancer. 6th
Biannual International Conference on Angiogenesis: Basic Science and Clinical
Developments.
41. New Zinc Metalloproteinases and the Inhibitors in Development, Angiogenesis
and Metastasis.
42. New Metalloproteinases in Human Endometrial, Breast, and Prostate Cancer
Cells and Rationally Designed Novel Metalloproteinase Inhibitors. Institute of
Experimental Oncology and Therapeutics, Technical
43. Human endometase/MMP-26 may be a novel marker for carcinoma diagnosis and a
new target for cancer treatment. 2nd General Meeting of the International
Proteolysis Society associated with the International Conference on Protease
Inhibitors. Freising,
44. Molecular, Enzymatic, and Functional Investigations of Endometase, a New
Carcinoma Matrix Metalloproteinase.
45. New
Metalloproteinases in Cancer Progression and Angiogenesis.
46. Novel
Metalloproteinases in Cancer.
47. How to Stop the Spread of Cancer?
48. Q.-X. Sang.
New metalloproteinases in prostate cancer invasion and angiogenesis. 15th
Annual Society for Basic Urologic Research Spring 2002 Meeting.
49. Ideas for Stopping Breast and Prostate Cancer
Invasion. A Story of Discovering Human
Endometase. American Cancer Society
Luncheon and Seminar.
50. New Ideas on How to Identify and Block
Invasive Cancers. American Cancer
Society Luncheon and Seminar.
51. Novel Functions of Matrix Metalloproteinases
and Adamalysins in Cancer and Cardiovascular Diseases. Mayo Clinic,
52. Mercaptosulfide Inhibitors as Probes
for Structure-Function Analysis of Endometase/Matrilysin-2.
53.
Endometase/Matrilysin-2: Roles in Cancer and Active Site
Structure-Function with New MMPIs. Gordon Research Conference on Matrix
Metalloproteinase. Big Sky,
54. Matrilysin-2/Endometase/MMP-26 in Human Cancer
and Reproduction. Department of Cancer
Biology,
55. Endometase/matrilysin-2 in cancer and
reproduction. Neuroscience Colloquium,
56. Metalloproteinases in
cancer and cardiovascular Diseases. Mayo
Clinic,
57. Discovery and
structural-functional properties of endometase/matrilysin-2, a potential
invasion marker.
58. Biology and Pathology of Matrix
Metalloproteinases (MMPs) and Extracellular Matrix (ECM).
59. MMPs and
60. MMPs in Human Breast Cancer.
61. New Hopes for MMPs as Therapeutic Targets for
Cancer, Cardiovascular, and other Diseases.
62. Endometase/matrilysin-2 in human breast and
prostate cancer invasion. Department of Biological Sciences and
63. The significance of myoepithelial cell layer
disruption in human breast cancer invasion; a paradigm shift from the
“protease-centered” hypothesis. Department of Biological Sciences and
64. Factors
involved in the initiation of human breast and prostate cancer invasion.
National Research Institute of Family Planning,
65. Metalloproteases
and non-protease factors in early stages of tumor invasion; new hypotheses on
the “mutated stem cells” and cancer drug resistance. Van Andel Research
Institute in
66. Prostate
basal cell layer disruptions and leukocyte infiltration (Endometase/matrilysin-2
in invasion and inflammation).
67. Inflammation, Cancer Stem Cells, and Tumor
Invasion.
68. A
story of endometase/ matrilysin-2/MMP-26.
69. Lessons from successful and failed grant
applications-tips on how to prepare better grant applications.
70. Leukocyte infiltration, mutated cancer stem
cells, and tumor progression. The Key Laboratory of Pathology and
71. Endometase/matrilysin-2
biochemistry and putative roles in cancer. The Key Laboratory of Enzyme Engineering
and Enzymology,
72. Lessons
and practical tips on how to prepare compelling grant applications and
manuscripts.
73. A new paradigm on the initiation of human
breast and prostate cancer invasion. Department of Biology,
74. Molecular characterization of human
endometase/matrilysin-2, a putative biomarker for carcinomas and embryo implantation.
National Institutes of Health (NIH).
75. Matrix
metalloproteinase-26 in human prostate and breast cancers, paradoxical roles in
invasion and survival. Center for Prostate Disease Research,
76.
Endometase/matrilysin-2, biomarker discovery, and new ideas on human breast and
prostate cancer apoptosis and invasion. Department of Pathology and Laboratory
of Medicine. University of
77. Biomarker
and enzyme inhibitor discovery for targeting human breast and prostate cancer
invasion using multidisciplinary approaches.
Department of Chemistry and Biochemistry, Montclair State University,
Montclair, New Jersey. March 8, 2007.
78. Discovery and Biochemical Characterization of Human Endometase/Matrilysin-2, a Putative Biomarker of Breast and Prostate Cancers. Department of Chemistry and Biochemistry, Florida State University, Tallahassee, FL. March 16, 2007.
79. Unique Structure and Function of Endometase/Matrilysin-2, a Putative Cancer Biomarker. Invited Talk. American Chemical Society, Florida Section Meeting, Orlando, Florida. May 11, 2007. Talk number 115.
80. Human Endometase/Matrilysin-2 as an Early Cancer Biomarker and Role of Leukocytes in Triggering Cancer Invasion. Oncology Research, MultiMedica Scientific and Technological Park, Milan, Italy. June 1, 2007.
81. Human Matrix Metalloproteinase-26 and Ideas on Initiation of Breast and Prostate Cancer Invasion. The Center of Experimental Cancer Research in the University of Liège, Liège, Belgium. June 12, 2007.
82. Endometase/Matrilysin-2 as a Biomarker for Preinvasive Cancers of Human Breast and Prostate. Rega Institute for Medical Research, Catholic University of Leuven, Leuven, Belgium. June 13, 2007.
83. Human MMP-26 and MMP-9, myoepithelial and
basal cell layer disruption, and breast and prostate cancer invasion. Institut National de la Sante et de la
Recherche Medicale (INSERM), Universite Paris, Paris, France. June 18, 2007.
84. Endometase/Matrilysin-2/MMP-26 and other Biomarkers in Human Breast and Prostate Cancer Invasion and Progression. Department of Pathology, Cell Biology, and Pharmacology/Toxicology, University of Alabama at Birmingham, Birmingham, Alabama. March 12, 2008.
85. Endometase/Matrilysin-2 as a Potential
Biomarker for Early Stage of Human Breast and Prostate Cancer. Marlene and
Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland.
July 16, 2008.
Back to the top
Honors, Awards, and
Professional Memberships:
I. Honors and Awards
1. Georgetown University Medical School Competitive Graduate Fellowship,
1986-1989.
2. Student Travel Award, American Society for Cell Biology, 1989.
3. Individual National Research Service Award, Public Health Service, National
Institutes of Health Individual Postdoctoral Fellowship, 1992-1993.
4. Henry F. Abel Research Award, American Caner Society, the
5. The RGK Foundation Award, 1994-1995.
6. Elsa U. Pardee Foundation Award, 1995.
7. The Gustavus and Louise Pfeifer Foundation Award, 1996.
8. Robert J. Boucek, M.D. Research Award, to the highest merit rated researcher
for the American Heart Association, Florida Affiliate, 1996-1997.
9. Elsa U. Pardee Foundation Award, 1997.
10. The Gustavus and Louise Pfeifer Foundation Award, 1997.
11. First-Year Assistant Professor Award,
12. FIRST Award (R29). National Cancer Institute, National Institutes of
Health. 1998-2003.
13. Travel Award from NATO Advanced Study Institute for attending a Conference
on Vascular Endothelium: Mechanisms of Cell Signaling,
14. The Gustavus and Louise Pfeifer Foundation Award, 1999.
15. Elsa U. Pardee Foundation Award, 2000.
16. Pilot Award, American Cancer Society,
17.
18.
19. Developing Scholar Award,
Florida State University, 2003-2004
20. Faculty Merit
Ranking #1, Department of Chemistry and Biochemistry, FSU, 2003-2004.
21. Faculty
Merit Ranking #2, Department of Chemistry and Biochemistry, FSU, 2004-2005.
22. Elsa U. Pardee Foundation Award,
2005.
23.
Susan G. Komen Breast Cancer Foundation Award, 2005-2007.
24.
Distinguished Faculty, Florida State University, 2006-2007.
25.
Distinguished Lecturer, Center for Prostate Disease Research, Walter Reed Army
Medical Center, Uniformed Services University of the Health Sciences,
Department of Defense. 2006.
26. Member,
The Deutscher Akademischer Austausch
Dienst (DAAD, German Academic Exchange Service) Research Tour 2006, “Science
in Germany: New Developments in Higher Education, Interdisciplinary Cooperation
and Industrial Application” December 3rd to December 9th, 2006.
27. Exploration-Hypothesis
Development Award, U.S. Army Prostate
Cancer Research Program (PCRP), Department of Defense, 2007-2009.
28. Initiated into the Honor
Society of Phi Kappa Phi, the nation's oldest, largest, and most selective
all-discipline honor society. Permanent member. April 5, 2007-present.
29. Faculty Merit Ranking #1, Department of Chemistry and Biochemistry,
FSU, 2006-2007.
II. Professional Memberships
1. Associate Member, American Society for Cell Biology, 1988-1992.
2. Member, American Society for Cell Biology, 1992-1997.
3. Associate Member, Sigma Xi, the Scientific Research Society, 1989-1991.
4. Member, Sigma Xi, the Scientific Research Society, 1991-1992.
5. Member of American Association for the Advancement of Science, 1995-2003
6. Member of American Society for Biochemistry and Molecular Biology, 1998-
7. Member of American Association for Cancer Research, 2001-
8.
Member of the International
Proteolysis Society, 2001-
Member/Reviewer of Grant
Peer Review Panels/ Study Sections and Scientific Journals
I. Member/Reviewer of Grant Peer Review
Panels/Study Sections
1. Member
of a grant Peer Review Panel of the U.S. Army Medical Research and Development
Command, Breast Cancer Research Program, U.S. Department of Defense.
2. Member
of a grant Peer Review Panel, National Action Plan on Breast Cancer, Office on
Women's Health and National Cancer Institute, NCI, NIH, PHS.
3. Member
of a grant Peer Review Panel of the U.S. Army Medical Research and Materiel
Command, Breast Cancer Research Program, U.S. Department of Defense.
4. Mail
Reviewer for the 1993 Breast Cancer
Research Program Awards Assessment and Monitoring
5. Mail
Reviewer for the
6. Member
of a grant Peer Review Panel of the U.S. Army Medical Research and Materiel Command,
Breast Cancer Research Program, U.S. Department of Defense.
7. Member
of a Review Panel for the Susan G. Komen Breast Cancer Foundation, the Basic,
Clinical and Transnational Research Panel. July-August, 1998.
8.
Member of a
grant Peer Review Panel of the U.S. Army Medical Research and Materiel Command,
Breast Cancer Research Program, U.S. Department of Defense.
9.
Member of a
Review Panel for the Susan G. Komen Breast Cancer Foundation, the Basic,
Clinical and Transnational Research Panel Reviewing 1998 Grant Extension
Applications.
10.
Member of a
grant Peer Review Panel of the U.S. Army Medical Research and Materiel Command,
Breast Cancer Research Program, U.S. Department of Defense.
11.
Grant
reviewer for British national funding agency, Medical Research Council,
12.
Grant
reviewer for the American Chemical Society, the Petroleum Research Fund
(ACS-PRF AC proposals) and Research Corporation. 2002-present.
13.
Member of a
grant Peer Review Panel of the U.S. Army Medical Research and Materiel Command,
Breast Cancer Research Program, U.S. Department of Defense.
14.
Member of a
grant Peer Review Panel of the U.S. Army Medical Research and Materiel Command,
Breast Cancer Research Program, U.S. Department of Defense.
15.
Member of a
grant Peer Review Panel of the U.S. Army Medical Research and Materiel Command,
Prostate Cancer Research Program, U.S. Department of Defense.
16.
Member of a
grant Peer Review Panel of the U.S. Army Medical Research and Materiel Command,
Breast Cancer Research Program, U.S. Department of Defense.
17.
Scientist
Reviewer of a grant Peer Review Panel of the U.S. Army Medical Research and
Materiel Command, Prostate Cancer Research Program, U.S. Department of
Defense.
18.
Scientist
Reviewer of a grant Peer Review Panel of the U.S. Army Medical Research and
Materiel Command, Breast Cancer Research Program, U.S. Department of
Defense.
19.
Scientist
Reviewer of a grant Peer Review Panel of the U.S. Army Medical Research and
Materiel Command, Breast Cancer Research Program, Concept Award mechanism.
20.
Scientist
Reviewer of a grant Peer Review Panel of the U.S. Army Medical Research and
Materiel Command, Prostate Cancer Research Program, U.S. Department of
Defense.
21.
Scientist
Reviewer of a grant Peer Review Panel of the U.S. Army Medical Research and
Materiel Command, Breast Cancer Research Program, U.S. Department of Defense,
Congressionally-Directed Medical Research Program. March 18-20, 2007. Reston, Virginia.
22.
Scientist
Reviewer of a grant Peer Review Panel, the American Heart Association,
Southern/Ohio Valley. April 23-24, Tampa, Florida.
23.
Scientist
Reviewer of a grant Peer Review Panel of the U.S. Army Medical Research and
Materiel Command, Prostate Cancer Research Program, U.S. Department of Defense,
Congressionally-Directed Medical Research Program. August 12-14, 2007. Alexandria, Virginia.
24.
Scientist
Reviewer of a Grant Peer Review Panel of the U.S. Army Medical Research and
Materiel Command, Breast Cancer Research Program, U.S. Department of Defense,
Congressionally-Directed Medical Research Program. July 16-18, 2008. Reston, Virginia.
II. Reviewer of Scientific Journals
1.
Reviewer for
Protein Science, a publication of the
Protein Society. 1997-
2.
Reviewer for
The Journal of Biological Chemistry
by the American Society for Biochemistry and Molecular Biology, Inc. 1998-
3.
Reviewer for
Cancer Research, Academic Press. 1998-
4.
Reviewer for
The American Journal of Pathology,
Cellular and Molecular Biology of Disease.
The official publication of the American Society for Investigative
Pathology. 1998-
5.
Reviewer for
The American Journal of Physiology: Cell
Physiology. 1998-
6.
Reviewer for
the British Journal of Cancer, The
Clinical and Scientific Journal of the Cancer Research Campaign. 1998-
7.
Reviewer for
Biology of Reproduction, 2000-
8.
Reviewer for
Developmental Dynamics, 2000-
9.
Reviewer for
Investigative Ophthalmology and Visual
Science, 2001-
10.
Reviewer for
Journal of the National Cancer Institute,
2001-
11.
Reviewer for
the Journal of Molecular Biology Reports
(MOLE), Kluwer academic publishers, 2002-
12.
Reviewer for
the Journal of Molecular Biology,
2002-, Elsevier Science publishers.
13.
Reviewer for
Cell Research, 2002-
14.
Reviewer for Clinical
and Experimental Metastasis, Official Journal of the Metastasis Research
Society, 2002-
15.
Reviewer for
the Biological Chemistry, 2002-,
Walter de Gruyter publishers.
16.
Reviewer for
The Journal of Biological Chemistry,
an Official Journal of the American Society for Biochemistry and Molecular
Biology. 2002-
17.
Reviewer for
the Journal of Medicinal Chemistry,
an Official Journal of the American Chemical Society. 2002-
18.
Reviewer for
FEBS Letters, Federation of European Biochemical Societies. Published by
Elsevier Science B.V. 2002-
19.
Reviewer for Biochemical
Pharmacology, 2003-
20.
Reviewer for
Int. J. Cancer, 2003-
21.
Reviewer for European
Journal of Medicinal Chemistry, 2004-
22.
Reviewer for Biochemical Journal, 2004-
23.
Reviewer for Biological
Chemistry, 2005-
24.
Reviewer for the European Journal of Biochemistry, 2005-
25.
Reviewer for Cell
and Tissue Research, 2006-
26.
Reviewer for
Pathology – Research and Practice,
2008-present
27.
Reviewer for
ChemBioChem, 2008-present
Sang Lab 2006 Chemistry and
Biochemistry Newsletter and Lab Notes
We are pleased to report that Ziad J. Sahab and Yewseok
Suh have graduated with a Ph.D. degree in Bio-analytical Chemistry and Biochemistry,
respectively. Professor Qing-Xiang Amy Sang’s laboratory is welcoming two
smart graduate students, Suzan Marie
Semaan and Chi Ben. Our former
graduate student, Dr. Douglas R. Hurst (Ph.D. 2003), a Dorothy and Russell Johnsen Ph.D.
Dissertation Award recipient, is a winner of an Individual National Research Service Award/Postdoctoral Fellowship
from the National Institutes of Health (NIH), as a Postdoctoral Fellow at the
University of Alabama at Birmingham. Qiang
Cao, Seakwoo Lee, and Ziad J. Sahab have presented talks or
posters at American Chemical Society Meetings. Ziad has been selected for honorary recognition in “The National
Dean’s List” again and has been elected to become an associate member of the
Sigma Xi. Seakwoo is making
remarkable progress in his Ph.D. dissertation research and is anticipated to
graduate during this new academic year. Robert
G. Newcomer received new 2006 awards including the Daisy Parker Flory Phi
Kappa Phi Graduate Scholar Award and the Joseph M. Schor Fellowship in
Biochemistry award. The AHA fellowship concluded, and he expanded that work
into a new collaboration with Dr. Joe
Schlenoff, through MARTECH. Qiang
Cao, Mark “Dru” Roycik and Daniel Trueblood are making very good progress as graduate
students. Mark “Dru” Roycik is a
straight A student. Danny won an “Outstanding Teaching
Assistant Award 2006”. The undergraduate
research student, Holly Monroe, is a
straight A student, a Katherine Blood and Harold H. Hoffman
Scholar, a Delos
F. and Frances L. DeTar Scholar., an
Undergraduate Research and Creativity Award recipient, and a cheerleader. Megan E. Muroski, the inaugural Bess Ward Research Fellow and Katherine Blood and Harold H. Hoffman
Scholar, had also won a Fisher
Fellowship to do human breast cancer research. Kevin K. Desai, a former honor’s in the major student working on a
prostate cancer research project and a recipient of Katherine Blood and Harold H. Hoffman Scholarship, James R. Fisher
Fellowship of the American Cancer Society, and John Mark Caffrey Scholarship,
is a graduate student in our department. Jennifer
Walker, a former Howard Hughes
Undergraduate Research Fellow in Mathematical and Computational Biology, is
now a medical student at FSU’s
